Login to Your Account



Regulatory NEWS

Should a state court be able to determine the legal precedent for the entire nation when it comes to injury claims against drug or device companies?

The docket for the FDA's most recent efforts to address the off-label question drew dozens of comments, many of which were at least modestly supportive of the changes in the agency's stance.

PERTH, Australia – Australia will save nearly A$500 million (US$379 million) over the next four years due to a deal hammered out by the federal government and pharmaceutical industry stakeholders.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: